Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine

被引:7
|
作者
Claesson, BA [1 ]
Trollfors, B
Lagergård, T
Knutsson, N
Schneerson, R
Robbins, JB
机构
[1] Sahlgrens Univ Hosp, Dept Infect Dis, S-41345 Gothenburg, Sweden
[2] Sahlgrens Univ Hosp, Dept Pediat, S-41345 Gothenburg, Sweden
[3] Sahlgrens Univ Hosp, Dept Med Microbiol & Immunol, S-41345 Gothenburg, Sweden
[4] Sahlgrens Univ Hosp, Dept Primary Hlth Care, S-41345 Gothenburg, Sweden
[5] Univ Gothenburg, Gothenburg, Sweden
[6] NICHHD, NIH, Bethesda, MD 20892 USA
关键词
Haemophilits influenzae; tetanus toxoid; conjugate vaccine;
D O I
10.1097/01.inf.0000160955.26151.71
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IgG antibodies against Haemophilus influenzae type b (Hib) capsular polysaccharide (CPS) and tetanus toxoid (TT) were measured for 53 children, 10 years of age, before and I month after a booster dose of diphtheria-tetanus vaccine (DT). All children had been vaccinated at 3, 5 and 12 months of age with DT and a Hib-TT conjugate. Geometric mean concentrations of Hib CPS serum IgG antibody were 4.16 and 4.30 mu g/mL before and after the DT booster, respectively. The geometric mean concentration of TT IgG antibody increased from 0.09 IU/mL to 4.58 IU/mL (P < 0.001). Hib CPS IgG levels remained well above protective titers for 9 years after 3 doses of Hib-TT appropriately spaced in infancy. A booster dose of TT did not affect Hib CPS antibody concentrations but induced a pronounced IgG response against TT.
引用
收藏
页码:463 / 464
页数:2
相关论文
共 12 条
  • [1] THE ACQUISITION OF ANTI-PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE HAEMOPHILUS-INFLUENZAE TYPE-B AND TETANUS TOXOID ANTIBODIES, WITH AGE, IN THE UK
    HAZLEWOOD, M
    NUSRAT, R
    KUMARARATNE, DS
    GOODALL, M
    RAYKUNDALIA, C
    WANG, DG
    JOYCE, HJ
    MILFORDWARD, A
    FORTE, M
    PAHOR, A
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1993, 93 (02) : 157 - 164
  • [2] Serum antibodies in six-year-old children vaccinated in infancy with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine
    Claesson, BA
    Trollfors, B
    Anderson, PW
    Johansson, J
    Taranger, J
    Schneerson, R
    Robbins, JB
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (02) : 170 - 172
  • [3] PERSISTENCE OF SERUM ANTIBODIES ELICITED BY HAEMOPHILUS-INFLUENZAE TYPE B-TETANUS TOXOID CONJUGATE VACCINE IN INFANTS VACCINATED AT 3, 5 AND 12 MONTHS OF AGE
    CLAESSON, BA
    SCHNEERSON, R
    LAGERGARD, T
    TROLLFORS, B
    TARANGER, J
    JOHANSSON, J
    BRYLA, D
    ROBBINS, JB
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1991, 10 (08) : 560 - 564
  • [4] Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine
    Panpitpat, C
    Thisyakorn, U
    Chotpitayasunondh, T
    Fürer, E
    Que, JU
    Hasler, T
    Cryz, SJ
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2000, 78 (03) : 364 - 371
  • [5] ANTIBODIES AGAINST HAEMOPHILUS-INFLUENZAE TYPE-B AND TETANUS IN INFANTS AFTER SUBCUTANEOUS VACCINATION WITH PRP-T/DIPHTHERIA, OR PRP-OMP/DIPHTHERIA-TETANUS VACCINES
    CARLSSON, RM
    CLAESSON, BA
    IWARSON, S
    LAGERGARD, T
    KAYHTY, H
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (01) : 27 - 33
  • [6] Impact of routine vaccination against Haemophilus influenzae type b in The Gambia: 20 years after its introduction
    Zaman, Syed M. A.
    Howie, Stephen R. C.
    Ochoge, Magnus
    Secka, Ousman
    Bah, Alasana
    Baldeh, Ignatius
    Sanneh, Bakary
    Darboe, Saffiatou
    Ceesay, Buntung
    Camara, Haddy Bah
    Mawas, Fatme
    Ndiaye, Malick
    Hossain, Ilias
    Salaudeen, Rasheed
    Bojang, Kalifa
    Ceesay, Samba
    Sowe, Dawda
    Hossain, M. Jahangir
    Mulholland, Kim
    Kwambana-Adams, Brenda A.
    Okoi, Catherine
    Badjie, Siaka
    Ceesay, Lamin
    Mwenda, Jason M.
    Cohen, Adam L.
    Agocs, Mary
    Mihigo, Richard
    Bottomley, Christian
    Antonio, Martin
    Mackenzie, Grant A.
    JOURNAL OF GLOBAL HEALTH, 2020, 10 (01)
  • [7] Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children &lt; 2 years of age with, or without, a booster vaccination
    Vadrevu, Krishna Mohan
    Raju, Dugyala
    Rani, Sandhya
    Reddy, Siddharth
    Sarangi, Vamshi
    Ella, Raches
    Javvaji, Bhuvaneswara
    Mahantshetty, Niranjana S.
    Battu, Sudhakar
    Levine, Myron M.
    VACCINE, 2021, 39 (45) : 6682 - 6690
  • [8] HAEMOPHILUS-INFLUENZAE TYPE-B CARRIAGE AND IMMUNITY 4 YEARS AFTER RECEIVING THE HAEMOPHILUS-INFLUENZAE OLIGOSACCHARIDE-CRM(197) (HBOC) CONJUGATE VACCINE
    BARBOUR, ML
    BOOY, R
    CROOK, DWM
    GRIFFITHS, H
    CHAPEL, HM
    MOXON, ER
    MAYONWHITE, D
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1993, 12 (06) : 478 - 484
  • [9] A clinical trial examining the effect of increased total CRM197 carrier protein dose on the antibody response to Haemophilus influenzae type b CRM197 conjugate vaccine
    Usonis, Vytautas
    Bakasenas, Vytautas
    Lockhart, Stephen
    Baker, Sherryl
    Gruber, William
    Laudat, France
    VACCINE, 2008, 26 (35) : 4602 - 4607
  • [10] Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae
    Novotny, Laura A.
    Jurcisek, Joseph A.
    Godfroid, Fabrice
    Poolman, Jan T.
    Denoel, Philippe A.
    Bakaletz, Lauren O.
    VACCINE, 2006, 24 (22) : 4804 - 4811